Search Results 2711-2720 of 17684 for rheumatoid arthritis

  1. Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion - Mayo Clinic

    History of medication noncompliance or risk factor for noncompliance; Active malignancy; Allergy to rivaroxaban; Another indication for anticoagulation; Strong ...

  2. Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients with Refractory or Relapsed Neuroblastoma - Mayo Clinic

    ... factor; Peripheral absolute neutrophil count (ANC) ≥ 750/uL; Platelet count ≥ 75,000/uL (transfusion independent); Patients known to have bone marrow ...

  3. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495) - Mayo Clinic

    Has confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), c-ros oncogene 1- (ROS1-), or B isoform of rapidly ...

  4. A Study of MCLA-128 in Patients with Solid Tumors Harboring an NRG1 Fusion - Mayo Clinic

    Absolute neutrophil count ≥ 1.5 x 10^9 /L without colony stimulating factor support for at least 7 days prior to Screening;; Platelets ≥ 100 x 10^9 /L ...

  5. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic

    Clinically significant bleeding within 4 weeks of screening, current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors unless these ...

  6. Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy - Mayo Clinic

    ... factor receptor 2 (HER2). Patients must not have received any prior chemotherapy, or endocrine therapy for their current breast cancer. Patients who ...

  7. A Study of Minimally Invasive Pericardiotomy as a New Treatment for Heart Failure - Mayo Clinic

    Heart failure is primary factor limiting activity as indicated by answering # 2 to the following question: My ability to be active is most limited by: Joint ...

  8. A Study to Assess the Effectiveness and Safety of Golimumab in Pediatric Participants With Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    Contraindications to the use of golimumab or infliximab or anti-tumor necrosis factor (TNF-alpha) therapy per local prescribing information. Participating ...

  9. Publications

    Vitamin D insufficiency in CLL: a modifiable prognostic factor? Blood Adv 2024 Jul 23; 8 (14):3838-3839. View PubMed; Amano A, Makowski MS, Trockel MT, Menon ...

  10. Toward regeneration: Joint repair plus joint cell reboot - Mayo Clinic

    For more information. Bradley EW, et al. Deletion of the PH-domain and leucine-rich repeat protein phosphatase 1 (Phlpp1) increases fibroblast growth factor ( ...